Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients.
Fiche publication
Date publication
janvier 2016
Journal
OncoTargets and therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel, Dr LUPORSI Elisabeth
Tous les auteurs :
Kurtz JE, Soubeyran P, Michallet M, Luporsi E, Albrand H
Lien Pubmed
Résumé
Chemotherapy-induced anemia (CIA) is a frequent complication among cancer patients, with elderly patients more likely to suffer severe effects. Biosimilar erythropoiesis-stimulating agents lower costs of supportive cancer treatment, and thus are particularly relevant in the elderly cancer population, which is growing rapidly worldwide. The goal of this subanalysis was to compare the tolerability and effectiveness of an epoetin biosimilar for treating CIA in patients <70 years old vs patients ≥70 years old.
Référence
Onco Targets Ther. 2016 ;9:6689-6693